Answers are grounded in this paper and cite their sources.
Olmesartan-associated enteropathy shares many features with coeliac disease, including symptoms and immunopathogenic pathways, such as increased numbers of CD8+ cells and corresponding overexpression of IL15 by epithelial cells. Taken together, the treatment of epithelial cells with olmesartan medoxomil induces a response by intestinal epithelial cells that is similar to the innate effects of gluten upon the epithelium of coeliac patients.
No takes yet. Share an insight, caveat, or question.
Marietta et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: